Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Drug developers have been trying for years, often in failure, to develop and market a noninjectable form of insulin for diabetes. Recently, however, progress has been made on several fronts. (Learn more about that progress here.) Do you think we are coming close to the point when a noninjectable form of insulin will reach the market?